- Home
- / Kringle Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kringle Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥72.2 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 17, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| JPY | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 467.6M | 289.8M | 391.8M | 69.3M | 80.0M | 72.2M | |
| Cost of goods sold | 71.6M | 88.4M | |||||
| Gross profit | 467.6M | 218.2M | 303.4M | 69.3M | 80.0M | 72.2M | |
| Gross profit margin, % | 100.0% | 75.3% | 77.4% | 100.0% | 100.0% | 100.0% | |
| Operating expense total | 371.7M | 639.2M | 576.0M | 729.6M | 958.0M | 897.9M | 981.7M |
| EBITDA | (371.7M) | (171.6M) | (357.9M) | (426.2M) | (888.8M) | (817.9M) | (909.5M) |
| EBITDA margin, % | -36.7% | -123.5% | -108.8% | -1283.4% | -1021.9% | -1259.4% | |
| EBIT | (371.7M) | (179.0M) | (380.9M) | (434.6M) | (845.6M) | (755.7M) | (907.9M) |
| EBIT margin, % | -38.3% | -131.5% | -110.9% | -1221.1% | -944.2% | -1257.3% | |
| Interest income | 1.0K | 5.0K | 10.0K | 67.0K | |||
| Pre tax profit | (301.6M) | (116.3M) | (299.7M) | (330.3M) | (852.7M) | (755.0M) | (914.8M) |
| Income tax expense | 420.0K | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M |
| Net Income | (302.0M) | (117.8M) | (301.2M) | (331.8M) | (854.2M) | (756.5M) | (916.3M) |